Grupos Investigadores

Líneas de Investigación

  • Cáncer de próstata de alto riesgo
  • Cáncer de próstata órgano-confinado: caracterización morfológica y biológica
  • Inmunoterapia en cáncer de próstata
  • Nuevas terapias dirigidas al cáncer de próstata
  • Terapias de rescate trás fracaso de

Palabras Clave

  • Cáncer de próstata
  • Cáncer de próstata metastásico
  • Cáncer resistente a la castración
  • Radioterapia
  • Terapia focal

Publicaciones Científicas desde 2018

  • Autores: Villalabeitia Ateca, I.; Prieto Calvo, M.; Martínez de la Cuesta, Antonio; et al.
    Revista: CIRUGIA ESPAÑOLA
    ISSN: 0009-739X Vol.101 N° 2 2023 págs. 143 - 145
  • Autores: González Padilla, Daniel Antonio (Autor de correspondencia); Subiela, J. D.; González-Díaz, A.; et al.
    Revista: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
    ISSN: 1078-1439 Vol.40 N° 10 2022 págs. 463
  • Autores: Rotellar Sastre, Fernando (Autor de correspondencia); Lujan Colas, Juan; Almeida Vargas, Ana; et al.
    Revista: ANNALS OF SURGICAL ONCOLOGY
    ISSN: 1068-9265 Vol.29 N° 9 2022 págs. 5547
  • Autores: Orcajo-Rincón, J.; Rodríguez Fraile, María Macarena (Autor de correspondencia)
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.41 N° 2 2022 págs. 69 - 70
  • Autores: Aliseda Jover, Daniel; Álvarez-Cienfuegos Suárez, Francisco Javier (Autor de correspondencia); Vivas Pérez, Isabel; et al.
    Revista: REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS
    ISSN: 1130-0108 Vol.114 N° 3 2022 págs. 168 - 169
    Resumen
    A 56-year-old female was referred to our department with a five-month history of progressive abdominal pain related to physical exertion and copious meals. The pain was located in the mesogastric region and the right flank and remitted when the patient lay in the recumbent position with the knees bent. The patient reported nausea and a weight loss of 12 kg over the previous ten years. She had been diagnosed 18 years previously with hereditary leiomyomatosis and renal cancer and had undergone a hysterectomy and partial nephrectomy.
  • Autores: Orcajo-Rincón, J.; Rodríguez Fraile, María Macarena (Autor de correspondencia)
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.41 N° 2 2022 págs. 69 - 70
  • Autores: García Cortés, Ángel (Autor de correspondencia); Colombas Vives, Juan; Gutiérrez Castañé, Cristina; et al.
    Revista: ACTAS UROLÓGICAS ESPAÑOLAS (ENGLISH ED.)
    ISSN: 2173-5786 Vol.46 N° 5 2022 págs. 275 - 284
    Resumen
    Objetivos Evaluar los resultados de la prostatectomía radical asistida por robot (PRAR), y compararlos con los de la cirugía abierta (PRA) y laparoscópica (PRL). El interés no solo radica en los resultados oncológicos y funcionales de la serie, sino en la evaluación de la calidad de vida (QoL), la recuperación postoperatoria y la satisfacción personal de los pacientes con la intervención (PR), fundamentalmente. Métodos Se realizaron 685 PR en nuestro centro entre 2011-2018 (17,8% PRA, 22,2% PRL y 60% PRAR). Los pacientes fueron evaluados prospectivamente mediante seguimiento hasta abril de 2020, y con la realización un cuestionario múltiple a los 12 meses post-PR, que incluía ICIQ-SF, SHIM, IPSS, IQL y preguntas sobre el dolor, la recuperación postoperatoria y la satisfacción del paciente (SP). También se recogieron datos basales y postoperatorios relacionados con el paciente y el tratamiento, y se realizaron regresiones logísticas binomiales para las comparaciones 1 vs. 1 (PRA vs. PRAR y PRL vs. PRAR). Resultados Los pacientes tratados con PRAR tienen en general menos comorbilidades, menos agresividad tumoral, un requerimiento de mayor tiempo operatorio y un número mayor de márgenes quirúrgicos positivos que los pacientes tratados con PRA y PRL. Sin embargo, la PRAR supera a la PRA en: días de estancia hospitalaria (OR: 0,86; IC 95%: 0,80-0,94), disminución de hemoglobina (OR: 0,38; IC 95%: 0,30-0,47), tasas de transfusión (OR: 0,18; IC 95%: 0,09-0,34), complicaciones tempranas (p = 0,001), IQL (OR: 0,82; IC 95%: 0,69-0,98), función eréctil (OR: 0,41; IC 95%: 0,21-0,79), manejo del dolor (OR: 0,82; IC 95%: 0,75-0,89), recuperación postoperatoria (p < 0,001) y elección de un abordaje diferente (OR: 5,55; IC 95%: 3,14-9,80). La PRAR es superior a la PRL en: continencia urinaria (OR: 0,55; IC 95%: 0,37-0,82), IPSS (OR: 0,96; IC 95%: 0,93-0,98), IQL (OR: 0,76; IC 95%: 0,66-0,88), función eréctil (OR: 0,52; IC 95%: 0,29-0,93), recuperación posquirúrgica (p = 0,02 y 0,004), PS (p = 0,005; 0,002; y 0,03) y elección de un abordaje diferente (OR: 7,79; IC 95%: 4,63-13,13). Conclusiones Los hallazgos de nuestro estudio respaldan la efectividad de la PRAR sobre la PRL y/o la PRA de manera global, tanto en factores funcionales, como en la recuperación postoperatoria, la QoL y la PS. Los resultados oncológicos aún deben ser mejorados.
  • Autores: González Padilla, Daniel Antonio (Autor de correspondencia); Subiela, J. D.; Gonzalez-Diaz, A.; et al.
    Revista: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
    ISSN: 1078-1439 Vol.40 N° 7 2022 págs. 345.e19 - 345.e23
    Resumen
    Introduction: Mitomycin C (MMC) is one of the most frequently utilized intravesical chemotherapy drugs for the management of nonmuscle-invasive bladder cancer (NMIBC). Allergic reactions (Type 4 delayed hypersensitivity) are seldomly reported in the literature but not so infrequent in daily practice, its incidence has been increasing with the use of device-assisted hyperthermia. This study aims to identify the incidence, risk factors, and clinical characteristics of patients with allergic reactions to MMC. Patients and Methods: Single-center retrospective cohort from June 2014 to August 2018. Patients with intermediate or high-risk NMIBC were included. Patients received passive MMC (4 weekly and eleven monthly instillations of 40mg of MMC) or Chemo-hyperthermia (CHT) with MMC (6 weekly and 6-monthly instillations, heated at 43 degrees C [+/- 0.5 degrees C] using Combat BRS). Results: We included 258 patients (MMC = 157, CHT = 101) and found 7 (4.4%) suspected and 4 confirmed (2.4%) allergies in the passive MMC group and 11 suspected (10.9%) and 7 confirmed (6.9%) in the CHT group. The mean number of instillations received before developing the allergy was 6 in the passive MMC and 5 in the CHT group. Seven out of 18 suspected allergy cases were pseudo-allergic reactions with negative allergy tests. Early postoperative MMC instillation was associated with an increased risk of allergy (OR 2.47 [CI 1.39-4.36], P = 0.001), while neither history of atopy nor history of other medications allergy was found to increase the risk. Conclusion: MMC allergy risk is increased with the use of device-assisted hyperthermia with an incidence of 2.4% for passive MMC and 6.9% for CHT. History of prior allergies does not seem to increase the risk of developing MMC allergy. In this series 38% of suspected cases were found to be pseudo-allergic reactions, highlighting the need to confirm the diagnosis before definitively stopping the treatment. (C) 2022 Elsevier Inc. All rights reserved.
  • Autores: Seidensticker, M. (Autor de correspondencia); Steffen, I. G.; Bargellini, I.; et al.
    Revista: CURRENT ONCOLOGY
    ISSN: 1198-0052 Vol.29 N° 2 2022 págs. 565 - 577
    Resumen
    The value of gadoxetic acid in the diagnosis of hepatocellular carcinoma (HCC), based on perfusion criteria, is under dispute. This post-hoc analysis of the prospective, phase II, randomized, controlled SORAMIC study compared the accuracy of gadoxetic acid-enhanced dynamic magnetic resonance imaging (MRI) (arterial, portovenous, and venous phase only) versus contrast-enhanced computed tomography (CT) for stratifying patients with HCC to curative ablation or palliative treatment. Two reader groups (radiologists, R1 and R2) performed blind reads of CT and gadoxetic acid-enhanced MRI (contrast dynamics only). A truth panel, with access to clinical and imaging follow-up data, served as reference. Primary endpoint was non-inferiority (margin: 5% points) of MRI vs. CT (lower 95% confidence interval [CI] > 0.75) in a first step and superiority (complete 95% CI > 1) in a second step. The intent-to-treat population comprised 538 patients. Accuracy of treatment decisions was 73.4% and 70.8% for CT (R1 and R2, respectively) and 75.1% and 70.3% for gadoxetic acid-enhanced dynamic MRI. Non-inferiority but not superiority of gadoxetic acid-enhanced dynamic MRI versus CT was demonstrated (odds ratio 1.01; CI 0.97-1.05). Despite a theoretical disadvantage in wash-out depiction, gadoxetic acid-enhanced dynamic MRI is non-inferior to CT in accuracy of treatment decisions for curative ablation versus palliative strategies. This outcome was not subject to the use of additional MR standard sequences.
  • Autores: Geyer, T. (Autor de correspondencia); Kazmierczak, P. M.; Steffen, I. G.; et al.
    Revista: BIOMEDICINES
    ISSN: 2227-9059 Vol.10 N° 5 2022 págs. 1156
    Resumen
    Background: To investigate whole-body contrast-enhanced CT and hepatobiliary contrast liver MRI for the detection of extrahepatic disease (EHD) in hepatocellular carcinoma (HCC) and to quantify the impact of EHD on therapy decision. Methods: In this post-hoc analysis of the prospective phase II open-label, multicenter, randomized controlled SORAMIC trial, two blinded readers independently analyzed the whole-body contrast-enhanced CT and gadoxetic acid-enhanced liver MRI data sets of 538 HCC patients. EHD (defined as tumor manifestation outside the liver) detection rates of the two imaging modalities were compared using multiparametric statistical tests. In addition, the most appropriate treatment recommendation was determined by a truth panel. Results: EHD was detected significantly more frequently in patients with portal vein infiltration (21% vs. 10%, p < 0.001), macrovascular infiltration (22% vs. 9%, p < 0.001), and bilobar liver involvement (18% vs. 9%, p = 0.006). Further on, the maximum lesion diameter in patients with EHD was significantly higher (8.2 cm vs. 5.8 cm, p = 0.002). CT detected EHD in significantly more patients compared to MRI in both reader groups (p < 0.001). Higher detection rates of EHD in CT led to a change in management only in one patient since EHD was predominantly present in patients with locally advanced HCC, in whom palliative treatment is the standard of care. Conclusions: Whole-body contrast-enhanced CT shows significantly higher EHD detection rates compared to hepatobiliary contrast liver MRI. However, the higher detection rate did not yield a significant impact on patient management in advanced HCC.
  • Autores: Rodríguez Fraile, María Macarena (Autor de correspondencia); Tamayo Alonso, P.; Rosales Castillo, Juan Jose; et al.
    Revista: REVISTA ESPAÑOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR
    ISSN: 2253-654X Vol.41 N° 2 2022 págs. 126 - 135
    Resumen
    Prostate cancer (PC) is the most common tumor in men in the West and the fifth leading cause of cancer-related death. The use of PSMA radioligands has represented an important advance both in its diagnosis, through PET molecular imaging, and in its treatment in advanced stages of the disease. This article reviews the contribution of PET studies with PSMA radioligands in initial staging, in tumor detection in biochemical recurrence (elevation of PSA) after treatment with curative intent, and in the more advanced stages of the disease (castration resistant PC or CRPC). The contribution of PSMA radioligand therapy (PSMA-RLT) in CRPC patients who progress to standard therapy is also analyzed.
  • Autores: Guerrero-Ramos, F. (Autor de correspondencia); González-Padilla, D. A.; González-Díaz, A.; et al.
    Revista: WORLD JOURNAL OF UROLOGY
    ISSN: 0724-4983 Vol.40 N° 4 2022 págs. 999 - 1004
    Resumen
    Purpose The purpose of the study was to compare the outcomes of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) patients treated with BCG vs recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC). Methods A pilot phase II randomized clinical trial was conducted including HR-NMIBC patients, excluding carcinoma in situ. Patients were randomized 1:1 to receive intravesical BCG for 1 year (once weekly for 6 weeks plus subsequent maintenance) or HIVEC with 40 mg MMC, administered using the Combat BRS system (once weekly instillations were given for 6 weeks, followed by once monthly instillation for 6 months). Total recirculating dwell time for HIVEC was 60 min at a target temperature of 43 degrees +/- 0.5 degrees C. Primary endpoint was recurrence-free survival. Secondary endpoints were time to recurrence, progression-free survival, cancer-specific survival, and overall survival at 24 months. Adverse events were routinely assessed. Results Fifty patients were enrolled. Mean age was 73.5 years. Median follow-up was 33.7 months. Recurrence-free survival at 24 months was 86.5% for HIVEC and 71.8% for BCG (p = 0.184) in the intention-to-treat analysis and 95.0% for HIVEC and 75.1% for BCG (p = 0.064) in the per protocol analysis. Time to recurrence was 21.5 and 16.1 months for HIVEC and BCG, respectively. Progression-free survival for HIVEC vs BCG was 95.7% vs 71.8% (p = 0.043) in the intention-to-treat analysis and 100% vs 75.1% (p = 0.018) in the per protocol analysis, respectively. Cancer-specific survival at 24 months was 100% for both groups and overall survival was 91.5% for HIVEC vs 81.8% for BCG. Conclusion HIVEC provides comparable safety and efficacy to BCG and is a reasonable alternative during BCG shortages.
  • Autores: Borrego Gómez, J.; Romera, N.; Tellado, J. M.; et al.
    Revista: RADIOLOGIA
    ISSN: 0033-8338 Vol.64 N° 4 2022 págs. 300 - 309
    Resumen
    Background and aims: Magnetic resonance imaging (MRI) with gadoxetic acid is widely used in clinical practice in Spain for the diagnosis, treatment, and follow-up of patients with liver metastases, although its use varies. This paper aims to provide recommendations for the use of MRI with gadoxetic acid in the detection and diagnosis of liver metastases in clinical practice in Spain. Material and methods: This project was undertaken by a group of nine experts who analyzed a series of recommendations about the use of gadoxetic acid extracted from international consensus documents. From this analysis, the experts decided to reject, adopt, contextualize, or adapt each of the recommendations. Once established, the final recommendations were voted on by the same group of experts. Results: The experts reached a consensus about five recommendations related to the use of this imaging technique in the management of liver metastases in three clinical situations: (i) in the detection, (ii) in the diagnosis and preoperative characterization, and (iii) in the detection after a chemotherapy treatment. Conclusion: The results support a clinical benefit for MRI with gadoxetic acid in the detection of liver metastases, favoring preoperative planning, especially in metastases measuring less than 1 cm, thus facilitating early diagnosis of metastatic spread.
  • Autores: Rotellar Sastre, Fernando (Autor de correspondencia); Lujan Colas, Juan; Almeida Vargas, Ana; et al.
    Revista: ANNALS OF SURGICAL ONCOLOGY
    ISSN: 1068-9265 Vol.29 N° 9 2022 págs. 5543 - 5544
    Resumen
    Background: Laparoscopic liver surgery has progressively evolved. Consequently, liver procedures are increasingly performed laparoscopically, particularly in experienced centers. However, vascular resection and reconstruction still are considered a limitation for laparoscopy1 due to the risk of bleeding and the technical difficulty. Methods: A 72-year-old woman with a history of colorectal cancer had a 10 cm metastasis diagnosed in the right hemiliver with tumoral invasion of the right portal branch and tumor thrombus advancing to the portal confluence. After adjuvant chemotherapy and with stable disease, surgical resection was planned.2,3 Tips to avoid portal stenosis were carefully followed. Results: The operation was performed with a fully laparoscopic procedure. To minimize manipulation, an in situ right hepatectomy was performed.4 The right hepatic artery was dissected and ligated. The liver transection was guided with a caudal approach of the middle hepatic vein.5 The right biliary duct was then divided, achieving an excellent exposure of the portal bifurcation. The main and left portal trunks were occluded with vascular clamps, and the right portal vein was sharply divided with scissors. The stump was sutured to minimize backflow bleeding and to cover the tumor thrombus. Then, the portal opening was transversally sutured with a 5/0 running suture. The clamps were released, and the authors observed no bleeding and an adequate caliber with no stenosis. The procedure was completed in the standard fashion. The postoperative course was uneventful, and the woman was discharged on postoperative day 3. No early or late complications were observed.6 CONCLUSIONS: In selected cases, patients who require vascular resection and reconstruction during hepatectomies can benefit from the advantages of a laparoscopic approach.
  • Autores: Luis-Cardo, A. (Autor de correspondencia); Herranz-Amo, F.; Rodríguez-Cabero, M.; et al.
    Revista: ACTAS UROLOGICAS ESPAÑOLAS
    ISSN: 0210-4806 Vol.46 N° 6 2022 págs. 340 - 347
    Resumen
    Introducción y objetivos: Análisis comparativo de complicaciones postoperatorias y supervivencia entre nefrectomía parcial (NP) y radical (NR) laparoscópica en cáncer de células renales (CCR) cT1. Material y método: Estudio retrospectivo de pacientes birrenos con tumor renal único cT1 tratados en nuestro centro entre los a ¿nos 2005 y 2018 mediante NP o NR laparoscópica. Resultados: 372 pacientes cumplieron los criterios de inclusión para el estudio.156 (41,9%) fueron tratados mediante NR y 216 (58,1%) mediante NP. En 10 (4,6%) NP y 6 (3,9%) NR hubo complicaciones Clavien Dindo III-V (p = 0,75). El índice de Charlson se identificó como variable predictora independiente de complicaciones (p = 0,02), no influyendo el tipo de cirugía en el análisis multivariante. La estimación de la supervivencia global (SG) fue de 81,2% y de 56,8% a los 5 y 10 a ¿nos en el grupo de NR y de 90,2% y 75,7% en el grupo de NP respectivamente (p = 0,0001). Se identificaron como factores predictores de mortalidad global la obesidad (HR 2,77, p = 0,01), el índice Charlson ¿3 (HR 3,69,p = 0,001) y el FG <60 mL/min/1,73 m2 al alta (HR 1,87,p = 0,03). El tipo de nefrectomía no demostró influencia en la SG. La estimación de la supervivencia libre de recidiva (SLR) fue de 86,1% a los 5 y 10 a ¿nos en el grupo de NR y de 93,5% y 83,6% en el grupo de NP respectivamente (p = 0,22). Conclusiones: La NP laparoscópica no es inferior a la NR en términos de seguridad oncológica y quirúrgica en el CCR cT1. El tipo de nefrectomía no influyó en la SG del paciente, sin embargo, sí se comportaron como factores predictores la obesidad, el índice Charlson ¿3 y el FG <60 mL/min/1,73 m2 al alta.
  • Autores: Luis Cardo, A. (Autor de correspondencia); Herranz Amo, F.; Rodríguez Cabero, M.; et al.
    Revista: ACTAS UROLOGICAS ESPAÑOLAS
    ISSN: 0210-4806 Vol.46 N° 2 2022 págs. 63 - 69
    Resumen
    Introducción y objetivos Analizar la evolución de la función renal tras nefrectomía parcial (NP) y radical (NR) laparoscópica e identificar factores predictores de deterioro de función renal. Material y método Estudio retrospectivo de pacientes birrenos con filtrado glomerular (FG) > 60 mL/min/1,73 m2 y tumor renal único cT1 tratados en nuestro centro entre los años 2005 y 2018. Resultados 372 pacientes cumplieron los criterios de inclusión para el estudio. 156 (41,9%) fueron tratados mediante NR y 216 (58,1%) mediante NP. Al alta hubo una diferencia de 26,75 mL/min/1,73 m2 de FG entre NR y NP. La edad > 60 años, las complicaciones postoperatorias (OR 2,97, p = 0,005) y NR (OR 10,03, p = 0,0001) fueron factores predictores de FG<60 mL/min/1,73 m2 al alta. Únicamente la NR (OR 7,69, p = 0,0001) se comportó como factor pronóstico independiente de FG<45 mL/min/1,73 m2 al alta. La mediana de seguimiento de la serie fue de 57 (IQR 28 - 100) meses. Al final del seguimiento, nueve (6%) pacientes tratados con NR desarrollaron enfermedad renal crónica (ERC) grave y tres (2%) insuficiencia renal terminal (IRT). Edad > 70 años, diabetes mellitus (DM) (HR 2,12, p = 0,001), hipertensión arterial (HTA) (HR 1,73, p = 0,01) y NR (HR 2,88, p = 0,0001) se comportaron como factores predictores independientes de FG<60 mL/min/1,73 m2. Para un FG<45 mL/min/1,73 m2 fueron edad > 70 años, DM (HR 1,99 IC 95% 1,04 a 3,83, p = 0,04) y NR (HR 5,88 IC 95% 2,57 a 13,45, p = 0,0001). Conclusiones La NR es un factor de riesgo a corto y largo plazo de ERC, aunque con baja probabilidad de ERC grave o IRT en pacientes con FG > 60 mL/min/1,73 m2 preoperatoria. La edad, DM e HTA contribuyen al empeoramiento de la función renal durante el seguimiento.
  • Autores: Climent Durán, M. A. A.; Pérez Gracia, José Luis; Arranz Arija, J. A.; et al.
    Revista: JOURNAL OF CLINICAL ONCOLOGY
    ISSN: 0732-183X Vol.40 N° 6 2022
  • Autores: Beumer, B.; van Vugt, J.; Sapisochin, G.; et al.
    Revista: JOURNAL OF HEPATOLOGY (ONLINE)
    ISSN: 0168-8278 Vol.77 N° Supl. 1 2022 págs. S815 - S817
  • Autores: Pook, D. W.; Geynisman, D. M.; Carles, J.; et al.
    Revista: JOURNAL OF CLINICAL ONCOLOGY
    ISSN: 0732-183X Vol.40 N° 6 2022
  • Autores: Rosales Castillo, Juan Jose; Bastidas Tamayo, Juan Fernando; Bronte Viedma, Angela; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.49 N° Supl. 1 2022 págs. S483
  • Autores: Morales-Barrera, R.; Castellano, D. E.; O'Donnell, P. H.; et al.
    Revista: JOURNAL OF CLINICAL ONCOLOGY
    ISSN: 0732-183X Vol.40 N° 16 2022
  • Autores: Cruz, M.; Rosales Castillo, Juan Jose; Bastidas Tamayo, Juan Fernando; et al.
    Revista: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
    ISSN: 1619-7070 Vol.49 N° Supl. 1 2022 págs. S405 - S406
  • Autores: Andrés Boville, Guillermo; Barbas Bernardos, Guillermo; Herranz Amo, F.; et al.
    Revista: EUROPEAN UROLOGY
    ISSN: 0302-2838 Vol.81 N° Suppl. 1 2022 págs. S1219 - S1220
  • Autores: Miñana López, Bernardino; Andrés Boville, Guillermo; Barbas Bernardos, Guillermo; et al.
    Revista: EUROPEAN UROLOGY
    ISSN: 0302-2838 Vol.81 N° Suppl. 1 2022 págs. S500 - S501
  • Autores: Sotelo, M.; Alonso-Gordoa, T.; Gajate, P.; et al.
    Revista: CLINICAL AND TRANSLATIONAL ONCOLOGY
    ISSN: 1699-048X Vol.23 N° 4 2021 págs. 882 - 891
    Resumen
    Background The studies IMvigor 210 cohort 2 and IMvigor211 evaluated the efficacy of atezolizumab in patients with locally advanced or metastatic urothelial cancer (mUC) upon progression to platinum-based chemotherapy worldwide. Yet, the real impact of this drug in specific geographical regions is unknown. Materials and methods We combined individual-level data from the 131 patients recruited in Spain from IMvigor210 cohort 2 and IMvigor211 in a pooled analysis. Efficacy and safety outcomes were assessed in the overall study population and according to PD-L1 expression on tumour-infiltrating immune cells. Results Full data were available for 127 patients; 74 (58%) received atezolizumab and 53 (42%) chemotherapy. Atezolizumab patients had a numerically superior median overall survival although not reaching statistical significance (9.2 months vs 7.7 months). No statistically significant differences between arms were observed in overall response rates (20.3% vs 37.0%) or progression-free survival (2.1 months vs 5.3 months). Nonetheless, median duration of response was superior for the immunotherapy arm (non-reached vs 6.4 months;p = 0.005). Additionally, among the responders, the 12-month survival rates seemed to favour atezolizumab (66.7% vs 19.9%). When efficacy was analyzed based on PD-L1 expression status, no significant differences were found. Treatment-related adverse events of any grade occurred more frequently in the chemotherapy arm [46/57 (81%) vs 44/74 (59%)]. ...
  • Autores: Hevia Suárez, Mateo (Autor de correspondencia); Robles García, José Enrique; Chiva San Román, Santiago; et al.
    Revista: ACTAS UROLOGICAS ESPAÑOLAS
    ISSN: 0210-4806 Vol.44 N° 2 2020 págs. 103 - 110
    Resumen
    Introduction: Due to the absence of specific instruments to study the psychosocial sphere of patients undergoing extracorporeal shock wave lithotripsy (SWL), the objective of this study is to develop a satisfaction questionnaire regarding the SWL treatment from a health questionnaire which was already designed and had been previously validated. Material and methods: The design of the satisfaction questionnaire was carried out in 5 phases, based on a previously validated health scale in patients treated with SWL (ESPTL), including a total cohort of 135 patients treated at our center who received a phone interview. Phase 1: descriptive analysis of the series and scores of the 8 items of ESPTL. Phase 2: U-Mann Whitney comparison of ESPTL based on the patients' sex. Phase 3: study of ESPTL correlation with age using Spearman's Rho. Phase 4: grouping by factors of ESPTL, comparison by sex and correlation with age, as performed in phases 2 and 3 with the global score. Phase 5: obtaining the satisfaction subscate -SATISLIT-, descriptive analysis, comparison according to sex, correlation with age and linear regression model of SATISLIT with respect to ESPTL. Results: 135 patients, 85(63%) men, 50(37%) women. Median (minimum-maximum) age 56 (27-79) and ESPTL score 31 (8-39). Differences in global ESPTL score between men and women (p <.001), as well as in items 1 (p =.029), 3 (p =.002), 6 (p =.006), 7 (p =.005) and 8 (p =.025). Non-significant correlation of ESPTL regarding age. Significant correlation in items 2, 4, 5 and 8 but, very weak (<0.2). 4 factors, each one with 2 items, with statistically significant differences regarding sex in F2 (p =.001), F3 (p =.007) and F4 (p =.001). Significant correlation with age only in F1 and F3, but very weak (<0.2). Median (minimum-maximum) SATISLIT 18 (4-20). Statistically significant differences regarding patients' sex (p =.001). Non- significant correlation with age (p =.836). Significant linear regression of SATISLIT with respect to ESPTL (p <.001). Conclusions: Based on validated health questionnaire, the present work has provided a new instrument called SATISLIT for assessing patients' satisfaction after treatment with SWL. Future studies with external and temporal validation will be necessary to contrast its real clinical usefulness.
  • Autores: Garcia-Rojo, E.; Medina-Polo, J.; Sopena-Sutil, R.; et al.
    Revista: ACTAS UROLOGICAS ESPANOLAS
    ISSN: 1699-7980 Vol.43 N° 4 2019 págs. 176-181
  • Autores: Soria, F.; Villacampa Aubá, Felipe; Serrano, Á.; et al.
    Revista: ARCHIVOS ESPANOLES DE UROLOGIA
    ISSN: 1576-8260 Vol.71 N° 1 2018 págs. 89-96
    Resumen
    Current training in urological endoscopy lacks a specific training program. However, there is a clear need for a specific and uniform program, which will ensure the training, regardless of the unit where it is carried out. So, the goal is to first evaluate the current model and then bring improvements for update. The hospital training accreditation programme are only the adjustment of the official program of the urology specialty to the specific circumstances of each center, which causes variability in training of residents. After reviewing 19 training programs belonging to 12 Spanish regions. The current outlook shows that scarcely 10% of hospitals quantify the number of procedures/year, although the Spanish program emphasizes that the achievement of the residents should be quantified. Urology residents, sense their training as inadequate and therefore their level of satisfaction is moderate. The three main problems detected by residents as an obstacle on their training are: the lack of supervision, tutors completing their own learning. Finally, the lack of quantification in surgical activities is described as a threat. This has no easy solution, since the learning curve of the most common techniques in endourology is not correctly established. Regarding aspects that can improve the current model, they highlight the need to design a specific program. The need to customize the training, the ineludible accreditation of tutors and obviously dignify the tutor¿s teaching activity. Another basic aspect is the inclusion of new technologies as training tools, e-learning. As well as the implementation of an adequate competency assessment plan and the possibility of relying on simulation systems. Finally, they highlight the need to attend monographic meetings and external clinic rotations to promote critical training.
  • Autores: Ospina-Galeano, I.A.; Medina-Polo, J.; de la Rosa-Kerhmann, S.; et al.
    Revista: UROLOGIA COLOMBIANA
    ISSN: 0120-789X Vol.27 N° 1 2018 págs. 86-91
    Resumen
    Objective¿To assess the efficacy and safety of onabotulinum toxin A in patients with idiopathic overactive bladder inadequately managed with anticholinergics.Materials and Methods¿A prospective, open-label, single centre, and interventional study was conducted, from 2008 to 2013, on consecutive patients with idiophatic overactive bladder that showed lack of efficacy or intolerance to anticholinergic agents.Results¿The study included 73 female patients aged 58.9¿±¿12.9 years. A dose of 100 and 200 units of toxin were administered in 89 and 5 cases, respectively. Nineteen patients received a second injection, 8 patients received 3, and one patient was treated 4 times. Clinically, it was observed that 98% patients had urge urinary incontinence at baseline, as compared with 42% under treatment. Similar results were obtained regarding the number of pads used per day, from 2.8 at baseline to 0.5 after treatment as regards the urodynamic parameters, the first desire to void volume improved from 97¿±¿63 mL to 139¿±¿81 mL. Similar results were obtained as regards cystometric capacity and the volume of the first involuntary detrusor contraction. One patient had a positive urine culture resolved using a conventional oral antibiotic regimen. Intermittent catheterisation was required in 5 patients during the first week.Conclusions¿Onabotulinum toxin A injections significantly improved, not only the clinical symptoms, but also the urodynamic parameters in patients with idiopathic overactive bladder inadequately managed with anticholinergic drugs. This is a simple technique with minimal adverse effects and generally well tolerated.
  • Autores: Guerrero-Ramos, Felix; Castellano-Gauna, Daniel; Garcia-Rojo, Esther; et al.
    Revista: ARCHIVOS ESPANOLES DE UROLOGIA
    ISSN: 1576-8260 Vol.71 N° 4 2018 págs. 417 - 425
  • Autores: Pascual Piedrola, Juan Ignacio; Hevia Suárez, Mateo; Ancizu Marckert, Francisco Javier; et al.
    Revista: ARCHIVOS ESPANOLES DE UROLOGIA
    ISSN: 1576-8260 Vol.71 N° 8 2018 págs. 704 - 710
  • Autores: Unda-Urzai, M.; Cozar-Olmos, J. M.; Miñana López, Bernardino; et al.
    Revista: ACTAS UROLOGICAS ESPANOLAS
    ISSN: 1699-7980 Vol.42 N° 4 2018 págs. 238 - 248

Proyectos desde 2018

  • Título: RICORS2040
    Código de expediente: RD21/0005/0024
    Investigador principal: NURIA GARCIA FERNANDEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2021 AES Redes de Investigación cooperativa orientadas a resultados (RICORS)
    Fecha de inicio: 01-01-2022
    Fecha fin: 31-12-2024
    Importe concedido: 105.765,00€
    Otros fondos: Fondos FEDER
  • Título: Nuevas estrategias de radio-inmunoterapia para el tratamiento del fracaso loco-regional en cáncer de mama triple negativo
    Código de expediente: 34/2021
    Investigador principal: RAFAEL MARTINEZ MONGE.
    Financiador: GOBIERNO DE NAVARRA. DEPARTAMENTO DE SALUD
    Convocatoria: 2021 GN Proyectos de Investigación en salud
    Fecha de inicio: 23-12-2021
    Fecha fin: 22-12-2024
    Importe concedido: 69.550,00€
    Otros fondos: -
  • Título: Desarrolo preclinico y translacional de una estrategia inmunoterapia intratumoral consitente en la combinacion de BO-112 y agonistas de STING
    Código de expediente: PDC2021-121769-C22
    Investigador principal: JOSE LUIS PEREZ GRACIA.
    Financiador: AGENCIA ESTATAL DE INVESTIGACION
    Convocatoria: 2021 AEI Proyectos de I+D+i para la realización de pruebas de concepto
    Fecha de inicio: 01-12-2021
    Fecha fin: 30-10-2023
    Importe concedido: 25.000,00€
    Otros fondos: -
  • Título: Aplicaciones del estudio multi-ómico de la microbiota al desarrollo de soluciones biotecnológicas innovadoras en el área de la salud (microBiomics)
    Código de expediente: 0011-1411-2021-000106
    Investigador principal: MARIA TERESA HERRAIZ BAYOD.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2021 GN PROYECTOS ESTRATEGICOS DE I+D 2021-2024
    Fecha de inicio: 15-04-2021
    Fecha fin: 30-11-2023
    Importe concedido: 366.577,17€
    Otros fondos: -
  • Título: Registro prospectivo de hipofraccionamiento con fotonterapia y protonterapia con sobreimpresion en zona GaPSMA positiva en el rescate tras prostatectomia
    Código de expediente: pi20/01598
    Investigador principal: FELIX MAURICIO CAMBEIRO VAZQUEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2020 AES Proyectos de investigación
    Fecha de inicio: 01-01-2021
    Fecha fin: 31-12-2023
    Importe concedido: 68.970,00€
    Otros fondos: Fondos FEDER
  • Título: Identificación de biomarcadores para la detección de radionecrosis en pacientes tratados con radioterapia estereopática y desarrollo experimental de nuevas terapias para su prevención.
    Código de expediente: PI20/01531
    Investigador principal: JOSE JAVIER ARISTU MENDIOROZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2020 AES Proyectos de investigación
    Fecha de inicio: 01-01-2021
    Fecha fin: 31-12-2023
    Importe concedido: 123.420,00€
    Otros fondos: Fondos FEDER
  • Título: Administración intratumoral de agentes inmunoterápicos y radioterapia para potenciar los efectos sistémicos y locales antitumorales
    Código de expediente: PI20/00434
    Investigador principal: MARIA ESPERANZA RODRIGUEZ RUIZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2020 AES Proyectos de investigación
    Fecha de inicio: 01-01-2021
    Fecha fin: 31-12-2023
    Importe concedido: 111.320,00€
    Otros fondos: Fondos FEDER
  • Título: Liderazgo e INnovación en inmunoTERapia del cáncer desde NAvarra
    Código de expediente: 0011-1411-2020-000078
    Investigador principal: IGNACIO JAVIER MELERO BERMEJO.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2020 GN PROYECTOS ESTRATEGICOS DE I+D 2020-2022
    Fecha de inicio: 01-09-2020
    Fecha fin: 30-11-2023
    Importe concedido: 596.040,00€
    Otros fondos: -
  • Título: platafoRma de intElIgeNcia artiFicial para la predicción de tOxicidad y Recurrencia del CancE
    Código de expediente: 0011-1411-2020-000074
    Investigador principal: JAVIER RODRIGUEZ RODRIGUEZ.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2020 GN PROYECTOS ESTRATEGICOS DE I+D 2020-2022
    Fecha de inicio: 22-06-2020
    Fecha fin: 30-11-2023
    Importe concedido: 212.396,26€
    Otros fondos: -
  • Título: Evaluación de YES1 como nueva diana terapéutica y biomarcador de respuesta a dasanitib en cáncer de pulmón.
    Código de expediente: PI19/00230
    Investigador principal: ALFONSO CALVO GONZALEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2022
    Importe concedido: 127.050,00€
    Otros fondos: Fondos FEDER
  • Título: Modelando inmnunoterapia del cáncer de riñón en ratones humanizados
    Código de expediente: PI19/00668
    Investigador principal: MIGUEL FERNANDEZ DE SANMAMED GUTIERREZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2023
    Importe concedido: 111.320,00€
    Otros fondos: Fondos FEDER
  • Título: Neurodegeneración en epilepsia: ¿Una nueva Taupatía no descrita? Estudio in-vivo del depósito de proteina Tau en epilepsia temporal
    Código de expediente: PI19/00610
    Investigador principal: MARIA CENTENO SOLADANA, ASIER GOMEZ IBAÑEZ.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2022
    Importe concedido: 75.020,00€
    Otros fondos: Fondos FEDER
  • Título: Disección de los mecanismos de las recidivas locales post-resección y post braquiterapia.
    Código de expediente: PI19/01884
    Investigador principal: RAFAEL MARTINEZ MONGE.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: 2019 AES Proyectos de investigación
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2022
    Importe concedido: 93.170,00€
    Otros fondos: Fondos FEDER
  • Título: Ensayo clínico fase I/II: nuevo enfoque terapéutico para el tratamiento de tumores sólidos con metástasis hepática.
    Código de expediente: RTC2019-006860-1
    Investigador principal: MARIA ESPERANZA RODRIGUEZ RUIZ.
    Financiador: MINISTERIO DE CIENCIA E INNOVACIÓN
    Convocatoria: 2019 AEI RETOS COLABORACIÓN
    Fecha de inicio: 01-01-2020
    Fecha fin: 31-12-2023
    Importe concedido: 594.994,75€
    Otros fondos: -
  • Título: EHGNA: Desarrollo de Algoritmos de respuesta al tratamiento nutricional frente a la EHGna: integración de datos mediante inteligencia artificial
    Código de expediente: 0011-1383-2020-000010 PC082 EHGNA
    Investigador principal: ITZIAR ABETE GOÑI.
    Financiador: GOBIERNO DE NAVARRA
    Convocatoria: 2020 GN Proyectos Colaborativos
    Fecha de inicio: 01-12-2019
    Fecha fin: 30-11-2022
    Importe concedido: 193.350,00€
    Otros fondos: -
  • Título: Optimización de la radiembolización hepática mediante un modelo de simulación computacional
    Código de expediente: PI18/00692
    Investigador principal: JOSE IGNACIO BILBAO JAUREGUIZAR, MARIA MACARENA RODRIGUEZ FRAILE.
    Financiador: INSTITUTO DE SALUD CARLOS III
    Convocatoria: AES2018 PI
    Fecha de inicio: 01-01-2019
    Fecha fin: 31-12-2022
    Importe concedido: 59.290,00€
    Otros fondos: Fondos FEDER
  • Título: IL-8/CXCR pathway modulation plus CD137 co-stimulation as a way to overcome resistance to PD-1/PD-L1 pathway blockade in melanoma and kidney cancer patients
    Investigador principal: MIGUEL FERNANDEZ DE SANMAMED GUTIERREZ
    Financiador: ASOCIACION ESPAÑOLA CONTRA EL CANCER
    Convocatoria: 2021 AECC Lab AYUDAS A PROYECTOS DE INVESTIGACIÓN (Grupos emergentes)
    Fecha de inicio: 01-12-2021
    Fecha fin: 30-11-2024
    Importe concedido: 300.000,00€
  • Título: Nuevos biomarcadores para la determinación personalizada del riesgo de cáncer de pulmón en protocolos de cribado por TAC de baja dosis: desarrollo y validación de firmas proteicas de alta sensibilidad en combinación con análisis radiómico.
    Investigador principal: GORKA BASTARRIKA ALEMAÑ
    Financiador: ASTRA ZENECA FARMACEUTICA SPAIN, S.A.
    Convocatoria: 2021 ASTRA ZENECA - LUNG AMBITION ALLIANCE
    Fecha de inicio: 27-10-2021
    Fecha fin: 26-10-2024
    Importe concedido: 114.000,00€
  • Título: Rediseño del impacto de la radioterapia en el cáncer de mama con nuevos actores: Papel de las células tumorales circulantes (CTC) y nuevas vulnerabilidades de base mecanística.
    Investigador principal: RAFAEL MARTINEZ MONGE
    Financiador: ASOCIACION ESPAÑOLA CONTRA EL CANCER
    Convocatoria: 2021 AECC Proyectos Estratégicos
    Fecha de inicio: 01-10-2021
    Fecha fin: 30-09-2024
    Importe concedido: 150.000,00€
  • Título: Organ - specific biomarkers and therapies to improve the managemente of brain mestastasis
    Investigador principal: ALFONSO CALVO GONZALEZ
    Financiador: FUNDACIO "LA MARATO DE TV3"
    Convocatoria: 2019 FD LA MARATÓ PROYECTOS DE INVESTIGACIÓN
    Fecha de inicio: 22-09-2020
    Fecha fin: 21-09-2023
    Importe concedido: 125.000,00€
  • Título: Potenciación de la citotoxicidad dependiente de anticuerpo mediada por linfocitos nk para inmunoterapia del cáncer
    Investigador principal: IGNACIO JAVIER MELERO BERMEJO
    Financiador: ASOCIACION ESPAÑOLA CONTRA EL CANCER
    Convocatoria: 2015 AECC G Traslacionales
    Fecha de inicio: 01-07-2015
    Fecha fin: 30-06-2022
    Importe concedido: 334.000,00€